Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127293691 | 12729369 | 1 | I | 20140808 | 20160712 | 20160909 | 20160909 | EXP | FR-PFIZER INC-2016344001 | PFIZER | SASSIER, M.. CHEMOTHERAPY (PLATINUM AND PEMETREXED) IN COMBINATION WITH ERLOTINIB IN NON-SMALL CELL LUNG CANCER INDUCES MAJOR GASTROINTESTINAL TOXICITY: TWO CASE REPORTS FROM THE FLARE/GFPC 03-2013 STUDY. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016;41 (4):447-448 | 56.00 | YR | F | Y | 0.00000 | 20160909 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127293691 | 12729369 | 1 | I | PEMETREXED | PEMETREXED | 1 | 600 MG, CYCLIC (1ST COURSE) | U | 0 | 600 | MG | ||||||||
| 127293691 | 12729369 | 2 | I | PEMETREXED | PEMETREXED | 1 | 600 MG, CYCLIC (2ND COURSE) | U | 0 | 600 | MG | ||||||||
| 127293691 | 12729369 | 3 | I | CISPLATIN. | CISPLATIN | 1 | 90 MG, CYCLIC (1ST COURSE) | U | 0 | 90 | MG | ||||||||
| 127293691 | 12729369 | 4 | I | CISPLATIN. | CISPLATIN | 1 | 90 MG, CYCLIC (2ND COURSE) | U | 0 | 90 | MG | ||||||||
| 127293691 | 12729369 | 5 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | U | 76517 | |||||||||||
| 127293691 | 12729369 | 6 | I | ERLOTINIB | ERLOTINIB | 1 | 150 MG, 1X/DAY (ALONE) | U | 0 | 150 | MG | QD | |||||||
| 127293691 | 12729369 | 7 | I | ERLOTINIB | ERLOTINIB | 1 | UNK, CYCLIC (1ST COURSE) | U | 0 | ||||||||||
| 127293691 | 12729369 | 8 | I | ERLOTINIB | ERLOTINIB | 1 | UNK, CYCLIC (2ND COURSE) | U | 0 | ||||||||||
| 127293691 | 12729369 | 9 | I | APREPITANT. | APREPITANT | 1 | UNK | U | 0 | ||||||||||
| 127293691 | 12729369 | 10 | I | VERAPAMIL | VERAPAMIL HYDROCHLORIDE | 1 | UNK | U | 0 | ||||||||||
| 127293691 | 12729369 | 11 | C | PREDNISOLONE. | PREDNISOLONE | 1 | UNK | 0 | |||||||||||
| 127293691 | 12729369 | 12 | C | ONDANSETRON | ONDANSETRON | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127293691 | 12729369 | 1 | Non-small cell lung cancer metastatic |
| 127293691 | 12729369 | 3 | Non-small cell lung cancer metastatic |
| 127293691 | 12729369 | 5 | Non-small cell lung cancer metastatic |
| 127293691 | 12729369 | 6 | Non-small cell lung cancer metastatic |
| 127293691 | 12729369 | 9 | Antiemetic supportive care |
| 127293691 | 12729369 | 10 | Hypertension |
| 127293691 | 12729369 | 11 | Antiemetic supportive care |
| 127293691 | 12729369 | 12 | Antiemetic supportive care |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127293691 | 12729369 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127293691 | 12729369 | Asthenia | |
| 127293691 | 12729369 | Diarrhoea | |
| 127293691 | 12729369 | Drug interaction | |
| 127293691 | 12729369 | Nausea | |
| 127293691 | 12729369 | Renal failure | |
| 127293691 | 12729369 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127293691 | 12729369 | 1 | 20140806 | 0 | ||
| 127293691 | 12729369 | 2 | 20140827 | 20140916 | 0 | |
| 127293691 | 12729369 | 3 | 20140806 | 0 | ||
| 127293691 | 12729369 | 4 | 20140827 | 20140916 | 0 | |
| 127293691 | 12729369 | 6 | 201402 | 0 | ||
| 127293691 | 12729369 | 7 | 20140806 | 0 | ||
| 127293691 | 12729369 | 8 | 20140827 | 20140916 | 0 |